Artiva Biotherapeutics, Inc. 4

Director Elizabeth L. Hougen received a compensatory stock option award for 13,750 shares of Artiva Biotherapeutics, Inc. common stock at an exercise price of $10.88 per share.

On September 8, 2026, Director Elizabeth L. Hougen received a grant of a stock option covering 13,750 shares of Artiva Biotherapeutics, Inc. common stock at an exercise price of $10.88 per share. This director stock option, classified as an acquisition on the Form 4, is a compensatory award that will vest in full on the earlier of September 8, 2027, or the date of the issuer's 2027 annual stockholder meeting. Following the grant, Hougen holds 13,750 derivative securities (stock options) corresponding to 13,750 shares of common stock on a direct basis, with an aggregate intrinsic reference value of approximately $149,600 based on the option exercise price, though actual realizable value will depend on future market prices.

Filing Facts

CIK

1817241

Ticker

ARTV

Form

4

Source Type

fda

Accession

0001193125-26-385416

Alert Tier

5